Որոնման արդյունքները - Suzanne Trudel
- Ցուցադրվում են 1 - 20 արդյունքները 48
- Գնացեք Հաջորդ էջ
-
1
-
2
-
3
-
4
-
5
-
6
Clinical Outcomes in t(4;14) Multiple Myeloma: A Chemotherapy-Sensitive Disease Characterized by Rapid Relapse and Alkylating Agent Resistance Wilfrid Jaksic, Suzanne Trudel, Hong Chang, Young Trieu, Qi Xi, Joseph Mıkhael, Donna Reece, Christine Chen, A. Keith Stewart
Հրապարակվել է 2005Artigo -
7
CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma Suzanne Trudel, Zhihua Li, Ellen Wei, Marion Wiesmann, Hong Chang, Christine Chen, Donna Reece, Carla Heise, A. Keith Stewart
Հրապարակվել է 2004Artigo -
8
Phase I-II Trial of Bortezomib Plus Oral Cyclophosphamide and Prednisone in Relapsed and Refractory Multiple Myeloma Donna Reece, Giovanni Piza Rodriguez, Christine Chen, Suzanne Trudel, Vishal Kukreti, Joseph Mıkhael, Mariela Pantoja, Wei Xu, A. Keith Stewart
Հրապարակվել է 2008Artigo -
9
Second Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma: Impact on Progression-Free and Overall Survival Víctor H. Jiménez‐Zepeda, Joseph Mıkhael, Andrew Winter, Norman Franke, Esther Masih‐Khan, Suzanne Trudel, Christine Chen, Vishal Kukreti, Donna Reece
Հրապարակվել է 2011Artigo -
10
Exploiting the mevalonate pathway to distinguish statin-sensitive multiple myeloma James W. Clendening, Aleksandra A. Pandyra, Zhihua Li, Paul C. Boutros, Աննա Մարտիրոսյան, Richard Lehner, Igor Jurišica, Suzanne Trudel, Linda Z. Penn
Հրապարակվել է 2010Artigo -
11
The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development Pralay Mukhopadhyay, Hesham Abdullah, Joanna Opalinska, Prani Paka, Eric Richards, Katja Weisel, Suzanne Trudel, María‐Victoria Mateos, Meletios Α. Dimopoulos, Sagar Lonial
Հրապարակվել է 2025Revisão -
12
D(T)<scp>PACE</scp> as salvage therapy for aggressive or refractory multiple myeloma Alina S. Gerrie, Joseph Mıkhael, Lu Cheng, Haiyan Jiang, Vishal Kukreti, Tony Panzarella, Donna Reece, Keith Stewart, Young Trieu, Suzanne Trudel, Christine I. Chen
Հրապարակվել է 2013Artigo -
13
MIP-1α (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma Esther Masih‐Khan, Suzanne Trudel, Carla Heise, Zhihua Li, Joshua Paterson, Vincent Nadeem, Ellen Wei, David Roodman, Jaime O. Claudio, P. Leif Bergsagel, A. Keith Stewart
Հրապարակվել է 2006Artigo -
14
Immediate Utility of Two Approved Agents to Target Both the Metabolic Mevalonate Pathway and Its Restorative Feedback Loop Aleksandra A. Pandyra, Peter Mullen, Manpreet Kalkat, Rosemary Yu, Janice T. Pong, Zhihua Li, Suzanne Trudel, Karl S. Lang, Mark D. Minden, Aaron D. Schimmer, Linda Z. Penn
Հրապարակվել է 2014Artigo -
15
A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma Melissa Alsina, Suzanne Trudel, Richard R. Furman, Peter J. Rosen, Owen A. O’Connor, Raymond L. Comenzo, Alvin Wong, Lori Kunkel, Christopher J. Molineaux, André Goy
Հրապարակվել է 2012Artigo -
16
Antagonism of the Stat3–Stat3 Protein Dimer with Salicylic Acid Based Small Molecules Steven Fletcher, Brent D. G. Page, Xiaolei Zhang, Peibin Yue, Zhihua Li, Sumaiya Sharmeen, Jagdeep Singh, Wei Zhao, Aaron D. Schimmer, Suzanne Trudel, James Turkson, Patrick T. Gunning
Հրապարակվել է 2011Artigo -
17
Identification of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domain Brent D. G. Page, Steven Fletcher, Peibin Yue, Zhihua Li, Xiaolei Zhang, Sumaiya Sharmeen, Alessandro Datti, Jeffrey L. Wrana, Suzanne Trudel, Aaron D. Schimmer, James Turkson, Patrick T. Gunning
Հրապարակվել է 2011Artigo -
18
Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial Suzanne Trudel, Arleigh McCurdy, Martha L Louzada, Stephen Parkin, Darrell White, Michael P. Chu, Rami Kotb, Hira Mian, Ibraheem Othman, Jiandong Su, Aniba Khan, Engin Gul, Donna Reece
Հրապարակվել է 2024Artigo -
19
Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study Suzanne Trudel, Nikoletta Lendvai, Rakesh Popat, Peter M. Voorhees, Brandi Reeves, Edward N. Libby, Paul G. Richardson, Axel Hoos, Ira Gupta, Véronique Bragulat, Zangdong He, Joanna Opalinska, Adam D. Cohen
Հրապարակվել է 2019Artigo -
20
Pretreatment with Tocilizumab Prior to the CD3 Bispecific Cevostamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Showed a Marked Reduction in Cytokine Release Synd... Suzanne Trudel, Nizar J. Bahlis, Andrew Spencer, Rayan Kaedbey, Paula Rodríguez‐Otero, Simon J. Harrison, Chihunt Wong, Grant R. Goodman, Rin Nakamura, Voleak Choeurng, James Fenimore Cooper, María‐Victoria Mateos
Հրապարակվել է 2022Artigo
Որոնման գործիքներ:
Առնչվող խորագիր
Multiple myeloma
Medicine
Internal medicine
Oncology
Biology
Refractory (planetary science)
Cancer research
Astrobiology
Gastroenterology
Immunology
Genetics
Lenalidomide
Physics
Surgery
Adverse effect
Biochemistry
Cancer
Chemotherapy
Dexamethasone
Bortezomib
Gene
Pharmacology
Pomalidomide
Cell biology
Immunotherapy
Molecular biology
Antibody
Autologous stem-cell transplantation
Chemistry
Chimeric antigen receptor